Novo Nordisk A/S (NYSE:NVO) Sets New 1-Year Low – Here’s What Happened

Novo Nordisk A/S (NYSE:NVO)’s stock price hit a new 52-week low on Friday . The company traded as low as $59.32 and last traded at $61.12, with a volume of 9969565 shares traded. The stock had previously closed at $65.09.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Up 5.8 %

The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm has a market capitalization of $290.59 billion, a P/E ratio of 19.68, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The firm has a 50 day moving average price of $77.87 and a two-hundred day moving average price of $93.55.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.54%.

Institutional Trading of Novo Nordisk A/S

Large investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its position in Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock valued at $5,410,000 after buying an additional 23,223 shares during the period. Norman Fields Gottscho Capital Management LLC grew its stake in Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares in the last quarter. Bryn Mawr Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after purchasing an additional 30,420 shares during the period. Versant Capital Management Inc purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth approximately $86,000. Finally, Talbot Financial LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth approximately $4,066,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.